References
- Choi S, Kim DH, Lee HJ, Shin DJ. Anti-LGI1 antibody limbic encephalitis associated with hepatocellular carcinoma. J Korean Neurol Assoc 2020;38:272-275. https://doi.org/10.17340/jkna.2020.4.3
- van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MA, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 2016;87:1449-1456. https://doi.org/10.1212/WNL.0000000000003173
- Buckley C, Oger J, Clover L, Tuzun E, Carpenter K, Jackson M, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001;50:73-78. https://doi.org/10.1002/ana.1097
- Wong SH, Saunders MD, Larner AJ, Das K, Hart IK. An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry 2010;81:1167-1169. https://doi.org/10.1136/jnnp.2009.178293
- Gastaldi M, Thouin A, Vincent A. Antibody-mediated autoimmune encephalopathies and immunotherapies. Neurotherapeutics 2016;13:147-162. https://doi.org/10.1007/s13311-015-0410-6
- Navarro V, Kas A, Apartis E, Chami L, Rogemond V, Levy P, et al. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain 2016;139:1079-1093. https://doi.org/10.1093/brain/aww012